Reckitt Benckiser Pharmaceuticals and XenoPort Enter Into Global Licensing Agreement for Arbaclofen Placarbil

  Reckitt Benckiser Pharmaceuticals and XenoPort Enter Into Global Licensing
                      Agreement for Arbaclofen Placarbil

Reckitt Benckiser Pharmaceuticals Plans to Initiate Phase II Trial of Novel
Product Candidate as Potential Treatment for Alcohol Use Disorders

PR Newswire

RICHMOND, Va. and SANTA CLARA, Calif., May 15, 2014

RICHMOND, Va. and SANTA CLARA, Calif., May 15, 2014 /PRNewswire/ --Reckitt
Benckiser Pharmaceuticals Inc. and XenoPort, Inc. (NASDAQ: XNPT) announced
today that they have entered into a license agreement pursuant to which
Reckitt Benckiser Pharmaceuticals will be granted exclusive worldwide rights
for the development and commercialization of XenoPort's clinical-stage oral
product candidate arbaclofen placarbil for all indications. Arbaclofen
placarbil is a patent protected new chemical entity that Reckitt Benckiser
Pharmaceuticals plans to advance into a Phase IIB proof-of-concept study for
the treatment of alcohol use disorders – a condition affecting more than 140
million people worldwide.^[1],[2]

Alcohol use disorders are a global public health issue,^[2] with an annual
economic burden of $224 billion in the United States alone.^[3] Alcoholism is
directly responsible for more than 2.5 million deaths each year and is a
causal factor in over 60 other major types of disease.^[2] The current
treatment approach is predominantly psychosocial support and is largely
non-medicalized.^[4] The majority of healthcare professionals feel
underequipped to manage patients with substance abuse – including alcoholism –
based on currently available standards of care.^[4]

"Reckitt Benckiser Pharmaceuticals recognizes that there is a tremendous need
for more effective, well-tolerated treatment options among the growing patient
population with alcohol use disorders, and we believe arbaclofen placarbil is
a natural fit for our growing addiction treatment pipeline," said Shaun
Thaxter, CEO, Reckitt Benckiser Pharmaceuticals Inc. "Over the past decade, we
have demonstrated our leadership in the challenging addiction space by helping
patients struggling with the chronic disease of opioid dependence access
treatment. We are proud to focus our clinical development experience along
with our global regulatory and go-to-market infrastructure to potentially
bring arbaclofen placarbil to market as a new choice for the many patients
with alcohol use disorder^[1],[2] and the healthcare professionals who treat
them."

Arbaclofen placarbil will be tested for its ability to suppress alcohol
cravings, reduce alcohol intake and to possibly facilitate maintenance of
abstinence in alcohol dependent people.^[5],[6] In prior clinical trials,
arbaclofen placarbil has demonstrated attributes that may enable convenient
dosing, stable plasma exposure and good tolerability.^[7]

"We believe that Reckitt Benckiser Pharmaceuticals will be an excellent
partner for the further development of arbaclofen placarbil, given their track
record of success in the treatment of addiction disorders. XenoPort has
completed a substantial amount of preclinical, clinical pharmacology and
manufacturing work and has dosed over 1,300 human subjects with arbaclofen
placarbil in various clinical trials," said Ronald W. Barrett, Ph.D., CEO,
XenoPort, Inc. "We are very pleased to leverage this work with a partner that
now has an exciting opportunity to develop a potential new effective, safe and
conveniently dosed medicine that could address an important medical and
societal problem."

Under the terms of the agreement, Reckitt Benckiser Pharmaceuticals will
receive exclusive rights to develop and commercialize arbaclofen placarbil
worldwide for all indications, subject to certain rights by XenoPort to
negotiate with Reckitt Benckiser Pharmaceuticals on collaborations for
non-addiction indications. In exchange for these rights and upon effectiveness
of the agreement, XenoPort is entitled to receive an up-front, non-refundable
cash payment of $20 million and another $5 million upon the transfer of
certain technology and materials to Reckitt Benckiser Pharmaceuticals.
XenoPort also will be eligible to receive aggregate cash payments of up to $70
million upon the achievement by Reckitt Benckiser Pharmaceuticals of certain
development and regulatory milestones, as well as up to $50 million for
commercial milestones. In addition, XenoPort is entitled to receive tiered
double-digit royalty payments up to the mid-teens on a percentage basis on
potential future net sales of arbaclofen placarbil in the United States and
high single-digit royalty payments on potential future net sales outside the
United States.

The agreement is subject to review by the U.S. Government under the
Hart-Scott-Rodino Antitrust Improvements Act, as amended, and will become
effective only after clearing review.

About Reckitt Benckiser Pharmaceuticals Inc.
Reckitt Benckiser Pharmaceuticals Inc. is a specialty pharmaceutical company
with a decade of heritage in serving the opioid dependence treatment
community. Committed to expanding education and access to medical therapies,
the company innovates, manufactures and markets medications that, in
conjunction with counseling and psychosocial support, treat opioid dependence.
Reckitt Benckiser Pharmaceuticals Inc. continues to invest resources in
raising awareness of opioid dependence within the community, while also
sponsoring training programs for physicians to become certified to treat
opioid addicted patients. The company aims to help patients, while also
protecting communities from the financial and societal burdens of addiction
through mediation-assisted treatment, enabling opioid dependence to be managed
within mainstream medical practice. Reckitt Benckiser Pharmaceuticals Inc. is
a wholly owned subsidiary of Reckitt Benckiser Group plc, a global company
publicly traded on the UK stock exchange.

About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates for
the potential treatment of neurological disorders. XenoPort is currently
commercializing HORIZANT^® (gabapentin enacarbil) Extended-Release Tablets in
the United States and developing its novel fumaric acid ester product
candidate, XP23829, as a potential treatment for patients with
moderate-to-severe chronic plaque type psoriasis and/or relapsing forms of
multiple sclerosis. REGNITE^® (gabapentin enacarbil) Extended-Release Tablets
is being marketed in Japan by Astellas Pharma Inc. XenoPort's pipeline of
product candidates also includes a potential treatment for patients with
Parkinson's disease.

To learn more about XenoPort, please visit the website at www.XenoPort.com.

XenoPort Forward-Looking Statements
This press release contains "forward-looking" statements, including, without
limitation, all statements related to the anticipated effectiveness of
XenoPort's license agreement with Reckitt Benckiser Pharmaceuticals; Reckitt
Benckiser Pharmaceuticals' future clinical development program for arbaclofen
placarbil; the therapeutic and commercial potential of arbaclofen placarbil;
and XenoPort's receipt of potential future development, regulatory and
commercial milestone payments, as well as potential royalty payments.Any
statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements. Words such as
"believe," "could," "intend," "plans," "potential," "will" and similar
expressions are intended to identify forward-looking statements. These
forward-looking statements are based upon XenoPort's current expectations.
Forward-looking statements involve risks and uncertainties. XenoPort's actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation: risks related to the ability
of the parties to satisfy all the conditions to effectiveness of XenoPort's
license agreement with Reckitt Benckiser Pharmaceuticals, including clearance
under the Hart-Scott-Rodino Antitrust Improvements Act, as amended; the
difficulty and uncertainty of pharmaceutical product development and the
uncertain results and timing of clinical trials and other studies, including
the risk that success in preclinical testing and early clinical trials does
not ensure that later clinical trials will be successful; the uncertainty of
the FDA approval process and other regulatory requirements; the uncertain
therapeutic and commercial value of arbaclofen placarbil; XenoPort's
dependence on collaborative partners, including the risks that if Reckitt
Benckiser Pharmaceuticals were to breach or terminate the license agreement or
otherwise fail to successfully develop and commercialize products thereunder
and in a timely manner, XenoPort would not obtain the anticipated financial
and other benefits of the license agreement and the clinical development or
commercialization of arbaclofen placarbil could be delayed or terminated;as
well as risks related to future opportunities and plans, including the
uncertainty of future operating results. These and other risk factors are
discussed under the heading "Risk Factors" in XenoPort's Securities and
Exchange Commissionfilings and reports, including in its Quarterly Report on
Form 10-Q for the quarter endedMarch 31, 2014, filed with the Securities and
Exchange Commission on May 9, 2014. XenoPort expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in the
company's expectations with regard thereto or any change in events, conditions
or circumstances on which any such statements are based.

References

^[1] World Health Organization Press Release. WHO to meet beverage company
representatives to discuss health-related alcohol issues. January 31, 2003.
Accessed on May 6, 2014. Available at:
http://www.who.int/mediacentre/news/releases/2003/pr6/en/.

^[2] World Health Organization. Global status report on alcohol and health.
2011. Accessed on May 6, 2014. Available at:
http://www.who.int/substance_abuse/publications/global_alcohol_report/msbgsruprofiles.pdf?ua=1.

^[3] National Institute on Alcohol Abuse and Alcoholism. Alcohol Facts and
Statistics. Accessed on May 6, 2014. Available at:
http://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/alcohol-facts-and-statistics.

^[4] The National Center on Addiction and Substance Abuse at Columbia
University. Addiction Medicine: Closing the Gap between Science and Practice.
June 2012. Accessed on May 6, 2014. Available at:
http://www.casacolumbia.org/addiction-research/reports/addiction-medicine.

^[5] Heidbreder C. Recent Advances in the Pharmacotherapeutic Management of
Drug Dependence and Addiction. Current Psychiatry Reviews, 2005, 1, 45-67.

^[6] Johnson, B. Update on Neuropharmacological Treatments for Alcoholism:
Scientific Basis and Clinical Findings. Biochem Pharmacol. 2008 January 1;
75(1): 34–56.

^[7] Lal et al. The Journal of Pharmacology and Experimental Therapeutics.
Arbaclofen Placarbil, a Novel R-Baclofen Prodrug: Improved Absorption,
Distribution, Metabolism, and Elimination Properties Compared with R-Baclofen
330:911–921, 2009.

SOURCE Reckitt Benckiser Pharmaceuticals Inc.

Contact: Reckitt Benckiser Pharmaceuticals: IR Contact: Richard Joyce,
Director, Investor Relations, RB, Phone: +44 (0) 1753 217800, Email:
richard.joyce@rb.com; Media Contacts: Alana Rockland, Biosector 2, Phone:
212-845-5651, Email: ARockland@Biosector2.com; Alice Sofield, Biosector 2,
Phone: 703-861-5654, Email: ASofield@Biosector2.com; XenoPort IR Contact:
Jackie Cossmon, Phone: 408-616-7295, Email: ir@XenoPort.com
 
Press spacebar to pause and continue. Press esc to stop.